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Abstract
Background—A few other studies have reported the effects of anatomical and technical factors
on clinical outcomes of carotid artery stenting (CAS). This study analyzed the effect of these
factors on perioperative stroke/myocardial infarction/death after CAS.
Methods—This was a retrospective analysis of prospectively collected data of 409 of 456
patients who underwent CAS during the study period. A logistic regression analysis was used to
determine the effects of anatomical and technical factors on perioperative stroke, death, and
myocardial infarction (major adverse events [MAEs]).
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Results—The MAE rate for the entire series was 4.7% (19 of 409), and the stroke rate was 2.2%
(9 of 409). The stroke rate for asymptomatic patients was 0.46% (1 of 218; P = .01). The MAE
rates for patients with transient ischemic attack (TIA) were 7% (11 of 158) vs 3.2% (8 of 251) for
other indications (P = .077). The stroke rates for heavily calcified lesions were 6.3% (3 of 48) vs
1.2% (4 of 332) for mildly calcified/noncalcified lesions (P = .046). Differences in stroke and
MAE rates regarding other anatomical features were not significant. The stroke rate for patients
with percutaneous transluminal angioplasty (PTA) before embolic protection device (EPD)
insertion was 9.1% (2 of 22) vs 1.8% (7 of 387) for patients without (P = .07) and 2.6% (9 of 341)
for patients with poststenting PTA vs 0% (0 of 68) for patients without. The MAE rate for patients
with poststenting PTA was 5.6% (19 of 341) vs 0% (0 of 68) for patients without (P = .0536). The
MAE rate for patients with the ACCUNET (Abbott, Abbott Park, Ill) EPD was 1.9% (3 of 158) vs

Author Manuscript

Correspondence: Ali F. AbuRahma, MD, Department of Surgery, West Virginia University, 3110 MacCorkle Ave, SE, Charleston, WV
25304 (ali.aburahma@camc.org).
Author conflict of interest: none.
Presented at the Forty-first Annual Meeting of the Southern Association for Vascular Surgery, Naples, Fla, January 18–21, 2017.
AUTHOR CONTRIBUTIONS
Conception and design: AA, TD, NH, EA, JA, LD, AN, PS
Analysis and interpretation: AA, LD, PS
Data collection: TD, NH, EA, JA
Writing the article: AA
Critical revision of the article: AA, TD, NH, EA, JA, LD, AN, PS
Final approval of the article: AA, TD, NH, EA, JA, LD, AN, PS
Statistical analysis: AA, LD
Obtained funding: Not applicable
Overall responsibility: AA

AbuRahma et al.

Page 2

Author Manuscript

6.7% (16 of 240) for others (P = .029). The differences between stroke and MAE rates for other
technical features were not significant. A regression analysis showed that the odds ratio for stroke
was 0.1 (P = .031) for asymptomatic indications, 13.7 (P = .014) for TIA indications, 6.1 (P = .
0303) for PTA performed before EPD insertion, 1.7 for PTA performed before stenting, and 5.4 (P
= .0315) for heavily calcified lesions. The MAE odds ratio was 0.46 (P = .0858) for asymptomatic
indications, 2.1 for PTAs performed before EPD insertion, 2.2 for poststent PTAs, and 2.2 (P = .
1888) for heavily calcified lesions. A multivariate analysis showed that patients with TIA had an
odds ratio of stroke of 11.05 (P = .029). Patients with PTAs performed before EPD insertion had
an OR of 6.15 (P = .062). Patients with heavily calcified lesions had an odds ratio of stroke of 4.25
(P = .0871). The MAE odds ratio for ACCUNET vs others was 0.27 (P = .0389).
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Conclusions—Calcific lesions and PTA before EPD insertion or after stenting were associated
with higher stroke or MAE rates, or both. The ACCUNET EPD was associated with lower MAE
rates. There was no correlation between other anatomical/technical variables and CAS outcome.
Carotid artery stenting (CAS) has become an alternative to carotid endarterectomy (CEA)
and minimally invasive therapy for significant carotid stenosis, particularly in high-risk
surgical patients. Currently, ~9000 CAS procedures are performed annually in the United
States.1 With the publication of the Carotid Revascularization Endarterectomy vs stenting
Trial (CREST),2 a significant proportion of patients with severe carotid artery stenosis have
undergone CEA or CAS with somewhat similar results.2 Better selection of high-risk
surgical patients or high-risk CAS patients is critical in providing the best therapy for each
individual patient.

Author Manuscript

Because percutaneous transluminal angioplasty (PTA) is a key component of CAS
procedures and carries significant embolic risk,3–7 its use before or after stent deployment is
being scrutinized. Only a few studies have reported the effects of anatomical and technical
factors on the clinical outcomes of CAS. This study analyzed the effect of these factors on
perioperative stroke and on stroke, myocardial infarction (MI), and death (major adverse
events [MAEs]) after CAS.

METHODS

Author Manuscript

Between January 2004 and October 2015, 456 CAS procedures were performed at our
institution, and this was a retrospective analysis of prospectively collected data of 409 of
these CAS patients. We excluded 47 CAS patients because of missing data or no embolic
protection device (EPD) was used. This study was approved by the Institutional Review
Board of West Virginia University/Charleston Area Medical Center. Informed consent was
not necessary because all data were anonymous and no personal patient information was
identified.
Every effort was made to identify missing data (anatomical/technical factors) by a review of
the electronic medical records and progress notes at our Vascular Center of Excellence.
Indications for CAS were asymptomatic patients with ≥80% carotid artery stenosis and
symptomatic patients (transient ischemic attacks [TIAs] and stroke) with ≥50% ipsilateral
carotid stenosis by conventional arteriography or ≥70% stenosis by duplex ultrasound
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imaging in our Intersocietal Accreditation Commission-accredited vascular laboratory,
computed tomography angiography, or magnetic resonance angiography.
All patients were treated with aspirin (325 mg) and clopidogrel (75 mg) for 48 to 72 hours
before the procedure. Clopidogrel was continued for 30 days after the procedure, whereas
aspirin therapy was continued indefinitely.
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All CAS procedures were done according to their carotid trial protocol and using cerebral
protection devices. Overall, CAS was selected for high-risk surgical patients, which included
physiological high-risk (severe coronary artery disease, congestive heart failure with ejection
fraction of <30%, cardiopulmonary disease, etc) or anatomical high-risk (post-CEA
restenosis, high cervical lesions, tracheostomy, neck irradiation, or past cranial nerve
injury).8 It should be noted that the number of CEAs performed in our tertiary medical
center (950 beds) averaged 300 to 400 annually during the past 10 years. All demographic
and clinical characteristics were recorded.
Specific anatomical factors that may affect perioperative CAS outcomes were also recorded.
These included lesion length, lesion location, severity, calcification, and aortic arch type.
Lesion length was measured as the distance, in millimeters, from the proximal to the distal
shoulder of the lesion. Lesion location was defined at the distal common carotid artery or
proximal internal carotid artery (ICA), including the bulb, or a combination of the distal
common carotid and ICA (bifurcational lesion). They were also classified as right carotid or
left carotid lesions. Severity of carotid stenosis was classified as 50% to 69% or 70% to
99%. Target site calcification was defined as no or mild calcification vs heavily calcified
lesions (>50% circumferential calcification), which was based primarily on computed
tomography angiography or ultrasound imaging, or both.
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Aortic arch types were defined as type I arch when the vessels arise from the top of the arch,
type II when they arise between parallel planes delineated by the outer and inner curves of
the arch, and type III when they arise caudal to the inner surface of the arch or the ascending
aorta. CAS was done as a primary procedure or for post-CEA stenosis (the CEA in 44 of
147 patients was done in <24 months).
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The following technical factors were also identified and recorded: stent type (RX Acculink
[Abbott, Abbott Park, Ill], Xact [Abbott], and others), number of stents (1 vs ≥2), stent
length, stent diameter, EPD type (RX ACCUNET [Abbott], Emboshield NAV6 [Abbott],
and others), EPD insertion to recovery time, pre-PTA before deployment of the distal EPD,
pre-PTA before stenting, PTA after stenting, or any combination of pre-PTA or post-PTA.
Prestenting PTA was done using 3- to 4-mm Viatrac balloons (Abbott) and poststenting PTA
using 5-mm balloons. No specific balloons were used for calcific lesions in this location.
Excluded from the analysis were 47 CAS in patients with significant stenosis in the proximal
common carotid artery or patients without the use of EPD.
Study end points
The primary end point of the study was 30-day perioperative stroke and the composite
outcome of MAEs, which included stroke, MI, or death, or a combination of these.
J Vasc Surg. Author manuscript; available in PMC 2018 August 01.
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Periprocedural neurologic evaluations were performed before and immediately after CAS
and at 24 to 48 hours after CAS. Minor stroke was defined as a neurologic deficit lasting
>24 hours, resulting in a grade I or II Rankin scale, and a major stroke as grades III to V
Rankin scale. Stroke was also referred to as an ipsilateral stroke if it affected the same
cerebral hemisphere of the carotid intervention or a contralateral stroke if it affected the
contralateral cerebral hemisphere.
Cardiac enzyme levels and electrocardiograms were obtained for all patients who were a part
of carotid clinical trials before the procedure and at 24 to 48 hours postoperatively. MI was
defined as electrocardiogram evidence of ischemia or patients with biomarker elevations
with chest pain. Every effort was made to follow the Society for Vascular Surgery Reporting
Standards for Carotid Intervention.8

Author Manuscript

Statistical analysis
A statistical analysis was performed using SAS 9.2 software (SAS Institute, Inc, Cary, NC).
A univariate analysis was performed on the effect of patient clinical and demographic
characteristics and anatomical and technical variables on perioperative outcome. Continuous
data are reported as means with a standard deviation. The 30-day stroke and MAE rates were
compared between various anatomical and technical variables. A logistic regression analysis
was also used to examine the correlation between these factors and outcomes, adjusting for
indications for CAS and various patient clinical and demographic characteristics. The
threshold for significance was 0.05.

RESULTS
Author Manuscript

Demographic and clinical predictors of perioperative stroke/MAE
Of 456 CAS procedures that were performed, 409 were analyzed. The perioperative stroke
rate for the entire series was 2.2% (9 strokes: 8 ipsilateral, 1 contralateral; 7 minor and 2
major) and the MAE rate was 4.7% (19 MAEs; 4 deaths, 9 strokes, and 6 MIs). The mean
age was 71.1 years (range, 51–84; median, 74 years) and 68.4 years for those without a
perioperative stroke (range, 40–88; median, 69; P = .345). The mean age was 71.5 years
(range, 51–84; median, 73 years) for patients who had perioperative MAEs and 68.3 years
for patients without perioperative MAEs (range, 40–88; median, 69 years; P = .1469).
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Table I summarizes the demographic and clinical characteristics in the entire series (409
CAS procedures). Table II summarizes the correlation between demographic and clinical
characteristics and perioperative stroke and MAE rates. As noted, the stroke rate for
asymptomatic patients was 0.46% vs 4.2% for symptomatic patients (P = .0144).
Meanwhile, the MAE rate for TIA patients was 7% vs 3.2% for other indications (P = .0774)
and was also higher for nonsmokers (P = .0297).
Because this study reported our 12-year experience during which new devices were
introduced, we analyzed the results according to three periods: 2001 to 2005, 2006 to 2010,
and 2011 to 2015. The perioperative stroke rates were 2.6% (2 of 77), 3.2% (5 of 156), and
1.1% (2 of 176), respectively (P = .4145), and MAE rates were 2.6% (2 of 77), 4.5% (7 of
156), and 5.7% (10 of 176), respectively (P = .5586).
J Vasc Surg. Author manuscript; available in PMC 2018 August 01.
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Table III summarizes the anatomical predictors of peri-operative stroke and MAE rates. As
noted, the stroke rate for heavily calcified lesions was 6.3% vs 1.2% for non-calcified (or
mildly calcified) lesions (P = .046). Forty-three of 250 patients (17.2%) with primary CAS
had heavily calcified lesions vs 4 of 129 (3.1%) for CAS for post-CEA restenosis (P < .
0001). There were no significant differences in stroke and MAE rates in regards to other
anatomical features.
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The distribution of lesion length was 46 lesions (11.4%) were <10 mm, 165 (41%) were
between 10 and <15 mm, 19 (4.7%) were between 15 and <20 mm, 116 (29%) were
between 20 and <30 mm, and 57 (14.1%) were ≥30 mm. The mean lesion length for patients
with perioperative strokes was 16.8 mm (range, 10–30 mm) vs 17.2 mm for patients who
had no strokes (range, 5–65 mm; P = .8792). The mean lesion length for patients with MAEs
was 15.5 mm (range, 5–39 mm) vs 17.2 mm (range, 5–65 mm) for patients without MAEs
(P = .2616). The mean percentage of stenosis for patients with peri-operative strokes was
84% (range, 60%–99%) vs 82.2% (range, 50%–99%; P = .4877) for patients without
strokes. Meanwhile, the mean percentage of stenosis for patients with MAE was 81%
(range, 60%–99%) vs 82.3% (range, 50%–99%; P = .6522) for patients without MAE.
There were also no significant differences in perioperative stroke and MAE rates according
to lesion location (right vs left carotid); however, left ICA lesions had a trend toward higher
stroke rates (3.1% vs 1.5%, P = .4584) and MAE rates (6.2% vs 2.9%, P = .1808).
Technical predictors of perioperative stroke/MAEs
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Table IV summarizes various technical factors that may affect perioperative stroke/MAE
rates. As noted, the stroke rate for patients with PTA before EPD insertion was 9.1% vs
1.8% for patients without (P = .0791) and 2.6% for patients with poststenting PTA vs 0% for
patients without (P = .3666). The MAE rate for patients with poststenting PTA was 5.6% vs
0% for patients without (P = .0536). MAE rates for patients with ACCUNET EPDs was
1.9% vs 6.7% for all other EPDs combined (P = .0291). There were no significant
differences in stroke and MAE rates in regards to stent type, number of stents used, stent
diameter, stent length, and time from EPD insertion to recovery time.
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The mean time between the deployment of the EPD and recovery was 14.7 minutes (range,
9–23 minutes) for patients who had perioperative strokes vs a mean of 14.9 minutes (range,
4–51 minutes; P = .8518) for patients without perioperative strokes. Meanwhile, the mean
recovery time for patients who had MAEs was 13 minutes (range, 5–23 minutes) vs 14.9
minutes (range, 4–51 minutes; P = .3548) for patients without MAEs.
To be noted, the technical factors for primary CAS and CAS for post-CEA restenosis were
similar, except that ACCUNET EPDs were used in 32.4% of patients for primary CAS vs
52.1% for CAS for post-CEA restenosis (P < .001), and stent length of ≥30 mm was used in
78.5% in primary CAS vs 56.2% for CAS for post-CEA restenosis (P < .001). There were
no significant differences between both groups in PTA before EPD insertion or post-PTA
stenting.
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Table V summarizes the correlation of early stroke/MAE rates and various PTAs, whether
before the deployment of the EPD, prestenting insertion, poststenting, or a combination of
the above.
Regression analysis

Author Manuscript

Table VI summarizes univariate and multivariate analyses for predictors of early stroke and
MAE rates. Regression univariate analysis showed that the odds ratio for stroke was 0.1 (P
= .031) for asymptomatic indications, 13.7 (P = .014) for TIA indications, 6.1 (P = .0303)
for PTAs performed before EPD insertion, 1.7 (P = .4413) for PTA performed before
stenting, and 5.4 (P = .0315) for heavily calcified lesions. It also showed that the MAE odds
ratio was 0.46 (P = .0858) for asymptomatic indications, 2.1 (P = .35) for PTAs performed
before EPD insertion, 2.2 (P = .2232) for poststent PTAs, and 2.2 (P = .1888) for heavily
calcified lesions. Multivariate analysis showed that TIA indications had an odds ratio of
stroke of 11.05 (P = .029), and PTA performed before EPD insertion had an odds ratio of
stroke of 6.15 (P = .062), whereas heavily calcified lesions had an odds ratio of stroke of
4.25 (P = .0871). The MAE odds ratio for ACCUNET EPD vs other filters was 0.27 (P = .
0389).

DISCUSSION

Author Manuscript

A comprehensive search of MEDLINE from January 1, 1996, through December 31, 2011,
by Khan and Qureshi1 showed that clinical factors, including age >80 years, symptomatic
status, diabetes mellitus, chronic renal failure, procedures done ≤2 weeks of symptoms, and
hemispheric TIA were associated with 30-day perioperative stroke and death. They also
found that certain angio-graphic factors, including left carotid artery intervention, ulcerated/
calcified plaques, lesion length >10 mm, stenosis >90%, ostial involvement, aortic arch type
III, aortic arch calcification, and ICA/common carotid artery angulation >60° were
predictors of increasing perioperative stroke. Other technical factors that were associated
with increasing perioperative stroke include the use of multiple stents, PTA without EPDs,
and PTA before stent placement. Meanwhile, intraprocedural use of EPDs and closed-cell vs
open-cell stent design were not associated with 30-day perioperative stroke or death, or
both.1

Author Manuscript

Our present study showed that the 30-day perioperative stroke rate for asymptomatic patients
was significantly lower than for symptomatic patients (0.46% vs 4.2%; P = .0144). Several
other carotid stent trials have shown that patients with symptomatic disease have higher 30day perioperative stroke or MAE rates, or both, compared with asymptomatic patients.2,9–12
However, a few studies have reported anatomical and technical factors and their effect on the
clinical outcomes of CAS. Our study analyzed the effect of these factors on perioperative
stroke and MAEs of CAS.
Anatomical predictors of CAS outcome
Naggara et al13 reported the results of a pooled analysis of 34,398 CAS patients and showed
that CAS for left ICA stenosis was associated with higher 30-day perioperative stroke/death
rates compared with CAS for right carotid artery stenosis (7.5% vs 6%). They suggested that
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this higher rate was secondary to the difficult access from the aortic arch to the left common
carotid artery. However, other studies have not found a significant difference in 30-day
stroke or death rates, or both, between right-and left-sided CAS.14,15
Our present study showed that the 30-day perioperative stroke rate for all left-sided lesions
was 2.6% vs 1.7% for right carotid lesions (P = .7371) and that the 30-day MAE rate was
6.1% for left carotid lesions vs 2.8% for right carotid lesions (P = .1164). The 30-day stroke
rate for left ICA lesions was 3.1% vs 1.5% for right ICA lesions (P = .4584) and the 30-day
MAE rate was 6.2% for left ICA lesions vs 2.9% for right ICA lesions (P = .1808). As
noted, there was a trend toward lower stroke and MAE rates in right carotid lesions
compared with left carotid lesions; however, the P value was not statistically significant,
which can be explained by the smaller sample size.
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It has also been noted that patients with aortic arch class III had a higher 30-day
perioperative stroke rate of 17.2% vs 8.1% for patients with aortic arch classes I and II in the
Endarterectomy vs Angioplasty in Patients With Symptomatic Severe Carotid Stenosis
(EVA-3S) trial.13 Our study did not show any significant difference according to aortic arch
type; however, most of our patients were done for aortic arch type I and II; with only 32
patients done for aortic arch type III.
Target site calcification has also been correlated with a higher 30-day stroke rate. A singlecenter study by Setacci et al16 noted that the presence of target site calcification was
associated with a higher 30-day perioperative stroke rate of 6.5% in contrast to 2.3% in
patients without calcification. Similar findings were noted in our present study, with a stroke
rate for heavily calcified lesions of 6.3% vs 1.2% for noncalcified or mildly calcified lesions
(P = .046).
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A few studies have reported the correlation of the severity of carotid stenosis and
perioperative CAS outcomes. Gray et al14 and Chaturvedi et al15 both reported no difference
in the mean severity of carotid stenosis and perioperative outcome. Similar findings were
noted in our study. However, a single-center study report by Mathur et al17 showed that CAS
performed for lesions with >90% stenosis was associated with a higher 30-day stroke rate of
14.9%, compared with 3.5% in patients with lesion severity of <90%.
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A few other studies15,17,18 have analyzed the correlation of CAS outcome and the target
lesion length and concluded that longer lesions were associated with a higher 30-day
perioperative stroke rate, particularly in octogenarians, as seen in the Carotid ACCULINK/
ACCUNET Post- Approval Trial to Uncover Unanticipated or Rare Events (CAPTURE) 2
trial.15 Mathur et al17 reported a 30-day stroke rate of 11.4% for lesions longer than 10 to 15
mm vs 3.8% for lesions shorter than 10 mm; whereas Sayeed et al18 reported a stroke rate of
17% vs 2.1%, and Setacci et al16 reported a stroke rate of 5.6% vs 2.6% for these lesions,
respectively.
Long lesions have been postulated to have a higher atherosclerotic burden, which leads to a
higher risk of dislodgement of emboli during PTA or stent placement, or both. Recently,
Moore et al19 reported the carotid angiographic characteristics in the CREST trial and the
major contributors to periprocedural stroke and death differences between CAS and CEA.
J Vasc Surg. Author manuscript; available in PMC 2018 August 01.
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They found that lesion length and lesions that were contiguous or sequential and
noncontiguous extending remote from the bulb were identified as influencing CAS to CEA
stroke and death treatment difference. For longer lesion lengths (≥12.85 mm), the risk of
CAS was higher than that of CEA (odds ratio, 3.42). They concluded that a higher stroke
and death rate for those treated with CAS appeared to be largely isolated to those with
longer lesions or those with sequential and remote lesions, or both. Our present study did not
show any significant correlation according to lesion length, which may be attributed to the
small sample size or because most of the treated lesions were <20 to 30 mm in length.
Technical predictors of CAS outcome
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Number, length, and types of stents—Stent design or the type of stent and its effect
on CAS outcome has been controversial. A multicenter study of 3179 patients concluded
that a free-cell area of >7.5 mm was associated with a higher 30-day stroke rate of 1.3% vs
3.4%, suggesting that closed-cell designed stents may be associated with a lower rate of
stroke20; however, in contrast, data from the Society for Vascular Surgery Registry did not
show any significant difference in CAS outcome, whether using open-cell or closed-cell
stent designs.21 Timaran et al,22 in a recent randomized controlled trial of 40 CAS patients
treated by closed-cell or open-cell design, found no significant difference in embolic events,
as documented by diffusion-weighted magnetic resonance imaging and transcranial Doppler.
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Our present study showed no significant differences in stroke and MAE rates in regards to
stent type, number of stents used, stent diameter, and stent length. To be noted, only 24
patients in our series had more than one stent. However, the CAPTURE registry study
reported that the use of multiple carotid stents was associated with a higher 30-day
perioperative stroke rate of 9.7%, compared with 4.5% in patients with only one stent
placement.13 Theoretically, that can be explained by the fact that multiple stents are a marker
of lesion length, which is generally associated with a higher rate of stroke events.
PTA before EPD insertion, pre-PTA or post-stenting PTA, or both—Our study
showed that the stroke rate for patients with PTA before EPD insertion was 9.1% vs 1.8%
for patients without and was 2.6% for patients with post-stenting PTA vs 0% for patients
without. The MAE rate for patients with post-stenting PTA was 5.6% vs 0% for patients
without (P = .0536). As noted, these results showed a significant trend toward a higher rate
of stroke in patients who underwent PTA before filter insertion and in MAE rates in patients
who had poststenting PTA. Our study also showed that the MAE rate for patients with the
ACCUNET filter was 1.9% vs 6.7% for all other filters combined (P = .0291).

Author Manuscript

A regression analysis model showed that the odds ratio of stroke was 6.1 (P = .0303) for
PTA performed before filter insertion, and 1.7 for PTA performed before stenting. It also
showed a MAE odds ratio of 2.1 for PTA before filter insertion and 2.2 for poststent PTA.
A multivariate analysis also showed that PTA performed before EPD insertion had an odds
ratio of stroke of 6.15 (P = .062). These findings only echo the fact that PTA before filter
insertion or before stenting, or both, and after stenting was associated with a significant
adverse event rate.
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The CAPTURE registry study14 noted that pre-PTA without EPD was associated with a
higher 30-day stroke rate of 15.4% compared with a stroke rate of 4.3% in patients without
pre-PTA. Similarly, Theiss et al23 showed that the pro-CAS registry data indicated that prePTA led to a higher periprocedural stroke rate of 4.1% vs 3%. Obeid et al7 recently
completed a retrospective analysis of CAS patients between 2005 and 2014 in the Vascular
Quality Initiative Database of 3772 patients and reported that poststent PTA was associated
with an increased periprocedural stroke and death rate of 3% overall, with a 2.4-fold
increase in perioperative stroke and death rates when prestent PTA only technique was
compared with prestenting PTA and poststenting PTA. Poststenting PTA is generally
believed to result in increased embolic showering and hemodynamic depression that may
persist into the postoperative period.
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Vos et al3 demonstrated that microembolization can occur during all phases of the CAS
procedure, starting with the wiring, the EPD insertion, prestenting PTA, stenting, and
poststenting PTA, as demonstrated by transcranial Doppler. It has also been suggested that
the most showering occurs during the poststenting PTA, because PTA fractures the plaque
and PTA may facilitate pushing some of the embolic material through the stent mesh.7
Our study has some limitations, including being a single-center study, which limits the
sample size. It is also a retrospective data analysis of prospectively collected data, and
reporting bias could lead to some errors. As indicated in the Results, the stroke rate was four
times higher in patients with primary CAS vs CAS for post-CEA restenosis, which may be
partially explained by the fact that there were more patients with calcific lesions in primary
CAS; however, this stroke rate was not statistically significant, which can be explained by
the sample size.

Author Manuscript

CONCLUSIONS
Calcific lesions and PTA before EPD insertion or post-stenting PTA were associated with a
higher stroke or MAE rate, or both, after CAS. The ACCUNET filter was associated with
lower MAE rates. No correlation was found between other anatomical and technical
variables and CAS outcome in our study.

Acknowledgments
We gratefully acknowledge Mary Emmett, PhD, for her assistance and Mona Lett for her editorial assistance in the
preparation of this manuscript.

References
Author Manuscript

1. Khan M, Qureshi A. Factors associated with increased rates of post-procedural stroke or death
following carotid artery stent placement: a systematic review. J Vasc Interv Neurol. 2014; 7:11–20.
[PubMed: 24920983]
2. Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooke W, et al. Stenting versus
endarterectomy for treatment of carotid artery stenosis. N Engl J Med. 2010; 363:11–23. [PubMed:
20505173]
3. Vos JA, van den Berg JC, Ernst SM, Suttorp MJ, Overtoom TT, Mauser HW, et al. Carotid
angioplasty and stent placement: comparison of transcranial Doppler US data and clinical outcome

J Vasc Surg. Author manuscript; available in PMC 2018 August 01.

AbuRahma et al.

Page 10

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

with and without filtering cerebral protection devices in 509 patients. Radiology. 2005; 234:493–9.
[PubMed: 15616120]
4. Mlekusch W, Schillinger M, Sabeti S, Nachtmann T, Lang W, Ahmadi R, et al. Hypotension and
bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther. 2003;
10:851–9. discussion: 860-1. [PubMed: 14658927]
5. Gupta R, Abou-Chebl A, Bajzer CT, Schumacher HC, Yadav JS. Rate, predictors, and consequences
of hemodynamic depression after carotid artery stenting. J Am Coll Cardiol. 2006; 47:1538–43.
[PubMed: 16630988]
6. Bussiere M, Lownie SP, Lee D, Gulka I, Lening A, Pelz DM. Hemodynamic instability during
carotid artery stenting: the relative contribution of stent deployment versus balloon dilation. J
Neurosug. 2009; 110:905–12.
7. Obeid T, Arnaoutakis DJ, Arhuidese I, Qazi U, Abularrage CJ, Black J, et al. Post-stent ballooning
is associated with increased peri-procedural stroke and death rate in carotid artery stenting. J Vasc
Surg. 2015; 62:616–23. [PubMed: 26033011]
8. Timaran CH, McKinsey JF, Schneider PA, Littooy F. Reporting standards for carotid interventions
from the Society for Vascular Surgery. J Vasc Surg. 2011; 53:1679–95. [PubMed: 21609800]
9. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al. Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid artery
stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004; 351:1493–501. [PubMed:
15470212]
10. Mas JL, Chatellier G, Beyssen B. Carotid angioplasty and stenting with and without cerebral
protection: clinical alert from the Endarterectomy Versus Angioplasty in Patients With
Symptomatic Severe Carotid Stenosis (EVA-3S) trial. Stroke. 2004; 35:e18–20. [PubMed:
14657456]
11. Ringleb PA, Allenberg J, Bruckmann H, Eckstein HH, Fraedrich G, et al. SPACE Collaborative
Group. 30-day results from the SPACE trial of stent-protected angioplasty versus carotid
endarterectomy in symptomatic patients: a randomized non-inferiority trial. Lancet. 2006;
368:1239–47. [PubMed: 17027729]
12. International Carotid Stenting Study Investigators. Carotid artery stenting compared with
endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting
Study): an interim analysis of a randomised controlled trial. Lancet. 2010; 375:985–97. [PubMed:
20189239]
13. Naggara O, Touze E, Beyssen B, Trinquart L, Chatellier G, Meder JF, et al. EVA-3S Investigators.
Anatomical and technical factors associated with stroke or death during carotid angioplasty and
stenting: results from the endarterectomy versus angioplasty in patients with symptomatic severe
carotid stenosis (EVA-3S) trial and systematic review. Stroke. 2011; 42:380–8. [PubMed:
21183750]
14. Gray WA, Yadav JS, Verta P, Scicli A, Fairman R, Wholey M, et al. CAPTURE Trial
Collaborators. The CAPTURE registry: predictors of outcomes in carotid artery stenting with
embolic protection for high surgical risk patients in the early post-approval setting. Catheter
Cardiovasc Interv. 2007; 70:1025–33. [PubMed: 18044758]
15. Chaturvedi S, Matsumura JS, Gray W, Xu C, Verta P. CAPTURE 2 Investigators and Executive
Committee. Carotid artery stenting in octogenarians: periprocedural stroke risk predictor analysis
from the multicenter Carotid ACCULINK/ ACCUNET Post Approval Trial to Uncover Rare
Events (CAPTURE 2) clinical trial. Stroke. 2010; 41:757–64. [PubMed: 20185789]
16. Setacci C, Cisci E, Setacci F, Iacoponi F, de Donato G, Rosi A. Siena carotid artery stenting score:
a risk modelling study for individual patients. Stroke. 2010; 41:1259–65. [PubMed: 20431079]
17. Mathur A, Roubin GS, Iyer SS, Piamsonboon C, Liu MW, Gomez CR, et al. Predictors of stroke
complicating carotid artery stenting. Circulation. 1998; 97:1239–45. [PubMed: 9570193]
18. Sayed S, Stanziale SF, Wholey MH, Makaroun MS. Angiographic lesion characteristics can predict
adverse outcomes after carotid artery stenting. J Vasc Surg. 2008; 47:81–7. [PubMed: 18178457]
19. Moore WS, Popma JJ, Roubin GS, Voeks JH, Cutlip DB, Jones M, et al. Carotid angiographic
characteristics in the CREST trial were major contributors to periprocedural stroke and death

J Vasc Surg. Author manuscript; available in PMC 2018 August 01.

AbuRahma et al.

Page 11

Author Manuscript

differences between carotid artery stenting and carotid endarterectomy. J Vasc Surg. 2016; 63:851–
7. [PubMed: 26610643]
20. Bosiers M, de Donato G, Deloose K, Berbist J, Peeters P, Castriota F, et al. Does free cell area
influence the outcome in carotidartery stenting? Eur J Vasc Endovasc Surg. 2007; 33:135–41.
[PubMed: 17097897]
21. Jim J, Rubin BG, Landis GS, Kenwood CT, Siami FS, Sicard GA. SVS Outcomes Committee.
Society for Vascular Surgery Vascular Registry evaluation of stent cell design on carotid artery
stenting outcomes. J Vasc Surg. 2011; 54:71–9. [PubMed: 21458198]
22. Timaran CH, Rosero EB, Higuera A, Ilarraza A, Modrall JG, Clagett GP. Randomized clinical trial
of open-cell vs closed-cell stents for carotid stenting and effects of stent design on cerebral
embolization. J Vasc Surg. 2011; 54:1310–6. [PubMed: 21723064]
23. Theiss W, Hermanek P, Mathias K, Bruckmann H, Dembski J, Hoffmann FJ, et al. Predictors of
death and stroke after carotid angioplasty and stenting: a subgroup analysis of the pro-CAS data.
Stroke. 2008; 39:2325–30. [PubMed: 18583556]

Author Manuscript
Author Manuscript
Author Manuscript
J Vasc Surg. Author manuscript; available in PMC 2018 August 01.

AbuRahma et al.

Page 12

Author Manuscript

HIGHLIGHTS
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•

Type of Research: Retrospective analysis of a prospectively collected singlecenter database

•

Take Home Message: In 409 patients, including 191 with symptoms, carotid
artery stenting resulted in a stroke rate of 2.2%. It was 6.3% for heavily
calcified lesions, 9.1% in those who received angioplasty before embolic
protection device placement and 2.6% in those who had angioplasty after
stenting.

•

Recommendation: This study suggests that heavily calcified carotid lesions
and angioplasty before embolic protection device placement or after stent
placement are risk factors for stroke and major adverse events after carotid
artery stenting.
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Table I

Author Manuscript

Demographic and clinical characteristics in the entire series (409 patients)
No. (%) or mean (range)
(N = 409)

Variable
Age, years

68.5 (40–88)

Male gender

241 (59)

Coronary artery disease

301 (74)

Hypercholesterolemia

321 (78)

Hypertension

365 (89)

Diabetes

182 (45)

Congestive heart failure

104 (25)

Chronic renal insufficiency

93 (23)

Smoking

248 (61)

Author Manuscript

Indication
Asymptomatic

218 (53)

TIA

158 (39)

Stroke

45 (11)

TIA, Transient ischemic attack.
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Table II

Author Manuscript

Demographic and clinical characteristics, perioperative stroke, and major adverse events (MAEs)
Parameter

Stroke, No. (%)

P value

MAEs, No. (%)

Gender

P value
.568

Male

5/236 (2.1)

Female

4/168 (2.4)

Coronary artery disease

1

10/241 (4.2)
9/168 (5.4)

1

Yes

7/301 (2.3)

No

2/108 (1.9)

Hypercholesterolemia

.9927
14/301 (4.7)
5/108 (4.6)

1

1

Yes

7/321 (2.2)

15/321 (4.7)

No

2/88 (2.3)

4/88 (4.6)

Author Manuscript

Hypertension

1

.4444

Yes

8/365 (2.2)

16/365 (4.4)

No

1/44 (2.3)

3/44 (6.8)

Diabetes

1

.7966

Yes

4/182 (2.2)

9/182 (5)

No

5/227 (2.2)

10/227 (4.4)

Congestive heart failure

.6986

Yes

3/104 (2.9)

No

6/305 (2)

Chronic renal insufficiency

1
5/104 (4.8)
14/305 (4.6)

1

1

Author Manuscript

Yes

2/93 (2.2)

4/93 (4.3)

No

7/316 (2.2)

15/316 (4.8)

Smoker

.1636

.0297

Yes

3/248 (1.2)

7/248 (2.8)

No

6/161 (3.7)

12/161 (7.5)

Indication
Asymptomatic

.0144

.1409

Yes

1/218 (0.46)

7/218 (3.2)

No

8/191 (4.2)

12/191 (6.3)

TIA

.0027

.0774

Yes

8/158 (5.1)

11/158 (7)

No

1/251 (0.4)

8/251 (3.2)

Stroke

1

1

Author Manuscript

Yes

1/45 (2.2)

2/45 (4.4)

No

8/364 (2.2)

17/364 (4.7)

TIA, Transient ischemic attack.
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Table III

Author Manuscript

Anatomical predictors of perioperative stroke and major adverse events (MAEs)
Predictor

Stroke, No. (%)

P value

MAE, No. (%)

P value

Lesion location
All lesions

.7371

.1164

Left sidea

6/230 (2.6)

14/230 (6.1)

Right sidea

3/179 (1.7)

5/179 (2.8)

ICA lesions only

.4584

Left side

5/161 (3.1)

Right side

2/137 (1.5)

Primary CAS

8/261 (3.1)

CAS for post-CEA

1/147 (0.7)

Author Manuscript

Preoperative stenosis

.1808
10/161 (6.2)
4/137 (2.9)

.1656

15/261 (5.8)

.1637

4/147 (2.7)
.4626

.3616

50%–69%

1/27 (3.7)

2/27 (7.4)

70%–99%

8/382 (2.1)

17/382 (4.5)

Lesion length
<15 mm

4/175 (2.3)

≥15 mm

5/228 (2.2)

<20 mm

6/230 (2.6)

≥20 mm

3/173 (1.7)

Target site calcification

1

12/175 (6.9)

.7380

14/230 (6.1)

7/228 (3.1)
.1588

5/173 (2.9)
.046

.2496

Heavy

3/48 (6.3)

4/48 (8.3)

None to mild

4/332 (1.2)

13/332 (3.9)

Author Manuscript

Aortic arch type

.0754

1

.4569

Type I

4/179 (2.2)

6/179 (3.4)

Type II

3/170 (1.8)

10/170 (5.9)

Type III

1/32 (3.1)

1/32 (3.1)

Unknown

1/28 (3.6)

2/28 (7.1)

CAS, Carotid artery stenting; CEA, carotid endarterectomy; ICA, internal carotid artery.
a

Includes all common carotid artery, carotid bifurcation, and ICA lesions.
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Table IV

Author Manuscript

Technical predictors of perioperative stroke and major adverse events (MAEs)
Predictor

Stroke, No. (%)

Type of EPD

P value

MAE, No. (%)

.0955a

.745

Accunetb

3/158 (1.9)c

3/158 (1.9)

Emboshield/NAV6b

4/198 (2)

13/198 (6.6)

Others (including Emboshield)

5/240 (2)

16/240 (6.7)

Type of stent

.7449
4/209 (1.9)

7/209 (3.4)

Xactb

4/155 (2.6)

10/155 (6.5)

Others

1/42 (2.4)

2/42 (4.8)

Author Manuscript

1

1

9/383 (2.4)

>1

0/24

Stent length

.0291d
.3827

ACCULINKb

Stents, No.

P value

1
18/383 (4.7)
1/24 (4.2)

.426

.7871

≤30 mm

3/119 (2.5)c

4/119 (3.4)c

>30 mm

4/284 (1.4)

13/284 (4.6)

PTA before EPD
Yes

2/22 (9.1)

No

7/387 (1.8)

.0791

2/22 (9.1)

.2721

17/387 (4.4)

PTA before stenting

Author Manuscript

Yes

6/244 (2.5)

No

3/165 (1.8)

.7451

12/244 (4.9)

.7501

7/165 (4.2)

PTA after stenting
Yes

9/341 (2.6)

No

0/68

.3666

19/341 (5.6)

.0536

0/68

EPD, Embolic protection device; PTA, percutaneous transluminal angioplasty.
a
Accunet vs Emboshield vs others.
b

Abbott, Abbott Park, Ill.

c
Two patients with stroke had missing stent length and one patient had missing type of EPD.
d

Accunet vs others.
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Table V

Author Manuscript

Percutaneous transluminal balloon angioplasty (PTA) combinations and perioperative stroke and major
adverse events (MAEs)
PTA

Stroke, No. (%)

MAE, No. (%)

None

0/26

0/26

Pre-EPD only

0/1

0/1

Prestent only

0/39

0/39

Poststent only

2/130 (1.5)

6/130 (4.6)

Pre-EPD and prestent

0/2

0/2

Pre-EPD and poststent

1/8 (12.5)

1/8 (12.5)

Prestent and poststent

5/192 (2.6)

11/192 (5.7)

Pre-EPD, prestent, and poststent

1/11 (9.1)

1/11 (9.1)

Author Manuscript

EPD, Embolic protection device.
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Table VI

Author Manuscript

Logistic regression analysis
Univariate: Early stroke
Variable

OR

95% CI

P value

Age

1.03

(0.96–1.11)

.4058

Gender (male vs female)

0.86

(0.23–3.24)

.8223

Hypertension

1.04

(0.13–8.52)

.9683

Coronary artery disease

1.33

(0.27–6.51)

.7215

Congestive heart failure

1.63

(0.4–6.61)

.4977

Hypercholesterolemia

1.10

(0.23–5.4)

.9026

Renal failure

1.00

(0.21–4.91)

.9971

Asymptomatic

0.10

(0.01–0.81)

.031

TIA

13.69

(1.7–110.47)

.014

Stroke

1.10

(0.14–9.02)

.9273

Preprocedure stenosis (70%–99% vs 50%–69%)

0.56

(0.07–4.6)

0.5852

Lesion length (≥15 mm)

0.96

(0.25–3.62)

.9501

Pre-PTA performed before EPD

6.09

(1.19–31.2)

.0303

Pre-PTA performed before stent

1.73

(0.43–7.01)

.4413

Target site calcification-heavy

5.4

(1.16–24.66)

.0315

Indication

Author Manuscript

Univariate: Early MI/stroke/death

Author Manuscript

OR

95% UCL

P value

Age

1.02

(0.97, 1.06)

.5127

Gender (male vs female)

1.00

(0.42, 2.38)

.9913

Hypertension

0.42

(0.15, 1.19)

.101

Coronary artery disease

1.01

(0.39, 2.65)

.981

Congestive heart failure

0.94

(0.34, 2.62)

.9102

Hypercholesterolemia

0.66

(0.26, 1.66)

.3781

Renal failure

1.34

(0.51, 3.51)

.5558

Asymptomatic

0.46

(0.19, 1.12)

.0858

TIA

2.04

(0.86, 4.82)

.1055

Stroke

Indication

Author Manuscript

0.88

(0.2, 3.87)

.8603

Preprocedure stenosis (70%–99% vs 50%–69%)

0.58

(0.13, 2.66)

.4833

Lesion length (≥15 mm)

0.43

(0.17, 1.12)

.0831

EPD (ACCUNETa vs other)

0.27

(0.08, 0.95)

.0413

Pre-PTA performed before EPD

2.07

(0.45, 9.45)

.35

Pre-PTA performed before stent

1.03

(0.44, 2.43)

.9463

Poststent PTA performed

2.16

(0.63, 7.43)

.2232

J Vasc Surg. Author manuscript; available in PMC 2018 August 01.

AbuRahma et al.

Page 19

Target site calcification

2.18

(0.68, 6.98)

.1888

Multivariate: Early stroke

Author Manuscript

OR

95% CI

P value

TIA indication

11.05

(1.28–95.47)

.029

Pre-PTA performed before EPD

6.15

(0.91–41.44)

.062

4.25

(0.81–22.32)

.0871

Target site calcification: heavy

Multivariate: Early MI/stroke/death

EPD: ACCUNET vs other

OR

95% LCL

P value

0.27

(0.08, 0.94)

.0389

CI, Confidence interval; EPD, embolic protection device; LCL, lower confidence limit; MI, myocardial infarction; PTA, percutaneous transluminal
balloon angioplasty; TIA, transient ischemic attack; UCL, upper confidence limit.
a
Abbott, Abbott Park, Ill.
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